Do Pharma Mergers and Acquisitions Improve R&D Productivity and Increase Shareholder Value?

WHITE PAPER

WHITE PAPER

Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial growth, and generate cost efficiencies.  The pharma industry has recently seen a flurry of significant M&As with more surely to follow. This white paper highlights the importance that M&As will have on the future performance of pharma companies. M&As will be required to achieve strategic objectives by augmenting and/or complementing existing company R&D pipelines as the risks and costs of developing new innovative medicines increase over time. The challenges for pharma companies are making the right targeting decisions for M&As and tactically ensuring such deals achieve strategic goals.

The objectives of this white paper are designed to help pharma executives in making critical M&A decisions by addressing five key questions:

  1. What is (will be) driving current and future M&A deals?
  2. Do M&As improve R&D productivity? If so, how? If not, why not?
  3. Do M&As increase shareholder value? If so, how? If not, why not?
  4. Are there any therapy classes that are more likely targets for increased M&A activity?
  5. What kinds of analyses should companies conduct when considering M&As in order to increase the probability of such deals improving R&D productivity and increasing shareholder value?

 

Complete the brief form to download the white paper.

Contact us at insights@axtria.com with any questions.

Get Your Copy!

Let Us Show You What Axtria’s 

Solutions Can Do For You